A Kuwaiti expert panel urges earlier screening and broader use of GLP-1 receptor agonists like semaglutide to manage the interlinked burden of obesity, diabetes, heart disease, and kidney disease.
75% of adults overweightKuwait faces one of the highest CKM disease burdens globally
What the researchers found
Expert consensus supports multidisciplinary CKM syndrome management with expanded GLP-1 RA access, particularly semaglutide, to address Kuwait's high burden of obesity and metabolic disease.
Why it matters
CKM syndrome affects millions worldwide, yet care remains fragmented across specialties. These recommendations provide a practical framework for integrated treatment in high-burden populations.
How the study worked
Expert consensus panel with literature review — Kuwaiti specialists in endocrinology, cardiology, and nephrology convened to assess barriers and define practical recommendations.
What this study cannot tell us
Expert consensus rather than original research data; recommendations are specific to Kuwait's healthcare context and may not directly apply to other settings.
How to read the evidence
Expert consensus statement based on literature review — provides clinical guidance but lacks the rigor of original clinical trial data.
When this study was published
Published 2026. Reflects current understanding of CKM syndrome and GLP-1 RA evidence.
The bigger picture
The CKM syndrome framework represents a paradigm shift from treating obesity, diabetes, heart disease, and kidney disease as separate conditions to managing them as interconnected metabolic disorders requiring coordinated care.
Questions still open
- How effective will multidisciplinary CKM care models be when implemented in Kuwait's primary care system?
- Will expanded GLP-1 RA access meaningfully reduce cardiovascular and renal endpoints in this population?
- Can these recommendations be adapted for other Gulf states with similar disease burdens?
Common questions
What is CKM syndrome?
Why do these experts recommend semaglutide specifically?
Read the original research
Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.
Diabetes therapy : research, treatment and education of diabetes and related disorders
Citation
Aldahi, Waleed A; Alenezi, Abdullah; Alessa, Thamer; Alhamdan, Rashed; Al-Humood, Khaldoon A; Alqallaf, Ahmed; Alotaibi, Torki; Alrajab, Heba; Alshammari, Abdulmuhsen M; Alyousef, Anas M; Alsayed Hashem, Asrar; Rizzo, Manfredi. (2026). Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.. Diabetes therapy : research, treatment and education of diabetes and related disorders. https://doi.org/10.1007/s13300-025-01838-0